Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADXS 31164
- Development stage
- Phase 2
- Lead developer
- OS Therapies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
ADXS 31164 is an investigational cancer immunotherapy classified as a cancer vaccine and antineoplastic agent. It is designed to target tumors that overexpress the HER2/ERBB2 receptor, functioning both as an ERBB2 (HER2) receptor antagonist and immunostimulant. The drug leverages a recombinant Listeria monocytogenes vector platform to stimulate the immune system against HER2-expressing tumor cells. Originally developed by the University of Pennsylvania, it has been further developed by OS Therapies for rare cancers such as osteosarcoma, where it holds orphan drug status. Clinical development has reached Phase III for osteosarcoma and Phase II for breast cancer, oesophageal cancer, and other solid tumors[1][3][5].
- Brand names
- OST-HER2OST-HER-2OST-HER 2
- Other names
- Lovaxin B
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ADXS 31164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADXS 31164.